CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4677454-cytomx-therapeutics-inc-ctmx-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 11, 2024 - CytomX Therapeutics, Inc. (NASDAQ:NASDAQ:CTMX) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ETCompany ParticipantsChris Ogden - Senior Vice...
0
Here's Why Investors May Bet on BioMarin (BMRN) Stock Now
https://www.zacks.com/stock/news/2215118/here-s-why-investors-may-bet-on-biomarin-bmrn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2215118
Jan 24, 2024 - Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.
0
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518
Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
0